Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by
- A decrease of virus titer in lung tissue after four days of treatment compared to vehicle control;
- Comparable efficacy in animals orally dosed twice daily vs dosed once daily; and
- Decreased lung weights in COR803 treated versus vehicle-treated animals, indicating improved pathology. Histopathological analysis is ongoing.
The target of COR803 is highly conserved across coronavirus strains observed to date and, therefore, has the potential to address both current and future coronavirus infection.
- A chemical reaction that leads to covalent irreversible binding of the viral 3CLpro enzyme;
- High potency: Antiviral EC90 of 12 nM in human lung cell viral replication assays;
- Broad spectrum activity against multiple coronaviruses;
- Highly selective for 3CLpro versus other cellular proteases, including Cathepsin L; and
- Excellent systemic exposure in preclinical models utilizing oral, intranasal or subcutaneous administration, allowing for clinical use in multiple settings, such as outpatient and inpatient.
Statements in this news release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this news release may be identified by the use of words such as “plan,” “potential,” “will,” “believe,” or other similar words. Examples of forward-looking statements include, among others; the potential therapeutic benefits, safety and efficacy of the company’s product candidates, including COR803, and partnership and licensing opportunities to support future development of COR803. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict and could cause actual results to differ materially from what the company expects. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in Cortexyme’s Quarterly Report on Form 10-Q filed with the